Literature DB >> 22499043

Is incident drug-resistance of childhood-onset epilepsy reversible? A long-term follow-up study.

Matti Sillanpää1, Dieter Schmidt.   

Abstract

Given the grave morbidity and mortality of drug-resistant epilepsy, it is of great clinical interest to determine how often prior proven drug-resistant epilepsy is reversible without surgery and whether remission can be predicted by clinical features in children with incident drug-resistant epilepsy. We determined the likelihood of 1-, 2- and 5-year seizure remission and terminal 5-year seizure remission after the first adequate drug regimen in a population-based cohort of 102 medically treated patients with incident, i.e. first-ever occurrence of drug-resistant epilepsy, as defined by the International League against Epilepsy. Among the 102 patients, 98 had focal seizures (68 symptomatic and 30 idiopathic/cryptogenic), one had generalized convulsive seizures and three had unclassified seizures. At the end of the 40.5-year median follow-up from the onset of adequate medication before the age of 16 years, 84 (82%) of 102 patients with incident drug-resistant epilepsy eventually entered one or more 1-year remissions, 81 (79%) one or more 2-year remissions, 70 (69%) one or more 5-year remissions and 52 (51%) of 102 5-year terminal remissions. In contrast, 18 (18%) of 102 patients with incident drug-resistant epilepsy never entered any 1-year remission, 21 (21%) 2-year remission, 32 (31%) 5-year remission and 50 (49%) of 102 any 5-year terminal remission. On multivariate analysis of clinical features, in every remission category, idiopathic or cryptogenic aetiology was the only significant predictor of entering remission. Incident drug-resistant epilepsy is eventually reversible in 49-79% of patients with mostly focal epilepsy, resulting in long-term remission of variable duration. Idiopathic or cryptogenic aetiology is a clinical predictor of reversible drug-resistant epilepsy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499043     DOI: 10.1093/brain/aws062

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  7 in total

1.  Are we too pessimistic about drug-resistant epilepsy?

Authors:  John W Miller
Journal:  Epilepsy Curr       Date:  2012-11       Impact factor: 7.500

2.  Impact of Drug Manipulation on Seizure Freedom in Adults with Uncontrolled Epilepsy: A Prospective Controlled Study in Rural China.

Authors:  Xiaoting Hao; Ziyi Chen; Bo Yan; Patrick Kwan; Dong Zhou
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

Review 3.  Surgical treatment of epilepsy.

Authors:  John W Miller; Shahin Hakimian
Journal:  Continuum (Minneap Minn)       Date:  2013-06

4.  International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy.

Authors:  Heidrun Potschka; Andrea Fischer; Wolfgang Löscher; Ned Patterson; Sofie Bhatti; Mette Berendt; Luisa De Risio; Robyn Farquhar; Sam Long; Paul Mandigers; Kaspar Matiasek; Karen Muñana; Akos Pakozdy; Jacques Penderis; Simon Platt; Michael Podell; Clare Rusbridge; Veronika Stein; Andrea Tipold; Holger A Volk
Journal:  BMC Vet Res       Date:  2015-08-28       Impact factor: 2.741

5.  Not all that glitters is gold: A guide to critical appraisal of animal drug trials in epilepsy.

Authors:  Aristea S Galanopoulou; Wenzhu B Mowrey
Journal:  Epilepsia Open       Date:  2016-10-27

6.  Impaired hippocampal functional connectivity in patients with drug resistant, generalized tonic-clonic seizures.

Authors:  Zhengge Wang; Xiaoyun Wang; Rong Rong; Yun Xu; Bing Zhang; Zhongyuan Wang
Journal:  Neuroreport       Date:  2019-07-03       Impact factor: 1.837

Review 7.  The right and the wrong with epilepsy and her science.

Authors:  Simon Shorvon; Dieter Schmidt
Journal:  Epilepsia Open       Date:  2016-08-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.